Organoids, Tissue Bioengineering and AI/ML Tools: Minimizing Animal Studies for Pharmacology / ADME / Tox in the Context of the FDA Roadmap
With the recent FDA memo on phasing out preclinical animal testing requirements for certain drugs and promoting the use of New Approach Methodologies (NAMs), the shift in broader strategy has brought new technologies to the forefront. This symposium covers a broad spectrum of NAMs, including organ-on-a-chip and AI/ML computation modeling, to reduce traditional animal studies..
